LIX1L (limb and CNS expressed 1 like) is a multifunctional RNA-binding protein with critical roles in metabolic and hepatic diseases. Primary Function: LIX1L functions as a post-transcriptional regulator controlling mRNA stability and miRNA expression 1. It localizes to cytoplasm and nucleoli, where it regulates ribosomal RNA synthesis and interacts with regulatory proteins 2. Mechanism: LIX1L employs distinct regulatory pathways depending on cellular context. In cholestasis, bile acid-induced LIX1L upregulation (via Egr-1 transcriptional activation) suppresses miR-191-3p, leading to increased bile acid synthesis 1. In metabolic dysfunction-associated steatohepatitis, PARP1-mediated poly-ADP-ribosylation enhances LIX1L stability, enabling CD36 mRNA stabilization to promote lipid accumulation 3. In hepatocellular carcinoma, LIX1L promotes glucose metabolism by suppressing FBP1 through miR-21-3p elevation 4. LIX1L also facilitates epithelial-mesenchymal transition through nucleolin-mediated ribosomal biogenesis 2. Disease Relevance: LIX1L elevation is associated with primary sclerosing cholangitis, primary biliary cholangitis, metabolic-associated fatty liver disease, and multiple cancer types 13. Clinical Significance: LIX1L and its regulatory pathways represent promising therapeutic targets for cholestatic liver disease, MASH-HCC progression, and EGFR-TKI-resistant lung cancer.